Arcus Biosciences (NYSE: RCUS) files Form 144 to sell 22,000 shares

Rhea-AI Filing Summary

Arcus Biosciences, Inc. (RCUS) has a planned sale under Rule 144 for 22,000 shares of common stock through E*TRADE Financial Corporation, with an aggregate market value of 481,800. Shares outstanding were 122,856,086 as indicated in the notice; this is a baseline figure, not the planned sale amount, and the exchange named is NYSE. The approximate sale date is 12/16/2025.

The shares to be sold were acquired on 12/15/2025 through the vesting of restricted stock grants originally awarded on 3/8/2022 and 1/23 of 2023, 2024 and 2025 in exchange for services rendered. Over the prior three months, The Juan Carlos Jaen and Anita Galeana 2000 Trust reported several sales of Arcus common stock, including 82,997 shares on 12/04/2025 for gross proceeds of 2,096,504.22.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 3005	22000	481800	122856086	12/16/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	12/15/2025	Vesting of restricted stock granted 3/8/2022	Arcus Biosciences, Inc.			7812	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2023	Arcus Biosciences, Inc.			11450	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2024	Arcus Biosciences, Inc.			10000	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2025	Arcus Biosciences, Inc.			12500	12/15/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Common Stock	12/04/2025	82997	2096504.22
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Common Stock	11/18/2025	5050	99760.23
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Common Stock	11/17/2025	44950	913028.9
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Common Stock	10/30/2025	4314	87638.91
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Common Stock	10/29/2025	77167	1617034.48
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Common Stock	10/29/2025	673	14102.71
The Juan Carlos Jaen and Anita Galeana 2000 Trust 3928 Point Eden Way Hayward CA 94545	Common Stock	10/28/2025	19019	372011.64

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Arcus Biosciences (RCUS) Form 144 filing disclose?

The notice discloses a planned Rule 144 sale of 22,000 shares of Arcus Biosciences common stock, with an aggregate market value of 481,800 and the NYSE named as the exchange.

How many Arcus Biosciences (RCUS) shares are planned for sale and through which broker?

The filing indicates that 22,000 common shares are to be sold through E*TRADE Financial Corporation, with an approximate sale date of 12/16/2025.

How were the Arcus Biosciences shares in this Form 144 acquired?

The shares were acquired on 12/15/2025 via vesting of restricted stock grants dated 3/8/2022 and 1/23 of 2023, 2024 and 2025, with the consideration described as services rendered.

How many Arcus Biosciences (RCUS) shares are outstanding according to the notice?

The Form 144 states that 122,856,086 shares or other units of Arcus Biosciences common stock were outstanding at the time of the notice.

What recent Arcus Biosciences stock sales by the trust are listed in the Form 144?

The filing lists several sales by The Juan Carlos Jaen and Anita Galeana 2000 Trust over the prior three months, including 82,997 common shares sold on 12/04/2025 for gross proceeds of 2,096,504.22.

Who is named as the seller in the recent Arcus Biosciences (RCUS) transactions?

The seller named for recent transactions is The Juan Carlos Jaen and Anita Galeana 2000 Trust, with multiple common stock sales reported between 10/28/2025 and 12/04/2025.